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ABSTRACT
Background: Nasal obstruction is considered the most serious problem for patients with allergic rhinitis. We
have previously established a model of nasal obstruction in guinea pigs. In the present study, we tried to estab-
lish an allergic model of nasal obstruction using Brown Norway (BN) rats to evaluate the effects of phosphodi-
esterase (PDE) 4 inhibitors in this model.
Methods: The volume of the nasal cavity was measured with an acoustic rhinometer. Decrease in the volume
of the nasal cavity was taken as nasal obstruction. BN rats were actively sensitized with ovalbumin conjugated
with aluminium hydroxide. Intranasal antigen instillation induced biphasic nasal obstruction in sensitized BN
rats.
Results: Early and late phase responses (EPR and LPR) were observed peaking at 0.5 and 6 hours after the
antigen challenge, respectively. Chlorpheniramine did not inhibit EPR or LPR at 10 mgkg, although the dose
was sufficient for the compound to exert its anti-histamine activity. Prednisolone inhibited both responses at 30
mgkg. Rolipram and CDP-840, PDE4 inhibitors, inhibited both responses at 100 mgkg. KF19514, a PDE14
dual inhibitor, inhibited EPR at 0.1 mgkg or more and inhibited LPR at 10 mgkg .
Conclusions: The present study provides a simple model of allergic biphasic nasal obstruction in BN rats,
and also suggests that the PDE4 inhibitor may alleviate nasal obstruction in patients with allergic rhinitis.
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INTRODUCTION
Allergic rhinitis is a very common disease. Approxi-
mately 20% of the population in industrialized coun-
tries suffers from this disease.1,2 Allergic rhinitis is
characterized by sneezing, rhinorrhea and nasal ob-
struction. When the specific antigen was applied to
the nasal cavity of patients with allergic rhinitis, over
90% showed immediate responses, such as sneezing,
rhinorrhea and nasal obstruction. Approximately 50%
showed late phase responses, such as severe nasal
obstruction . 3 Nasal obstruction is considered the
most serious problem for patients with rhinitis , be-
cause it is quite resistant to all types of drugs except
for steroids and decongestants.4
Several methods to evaluate the nasal obstruction
have been reported . 5-7 Among them , non-invasive
acoustic rhinometry was established , characterized
and has been used widely in patients with allergic
rhinitis.8,9 This technique was also applied to animal
models , such as guinea-pig models . 10 We have re-
cently reported an accurate measurement of nasal ob-
struction in guinea pigs11 and also validated the meth-
ods by evaluating various types of drugs.12-14 Brown
Norway (BN) rats have been widely used for allergic
asthma models because BN rats easily show Th2-
dominant IgE production, eosinophilia and airway hy-
perresponsiveness.15 However, there have been no
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Fig. 1　Schema of the measurement of the volume of the 
nasal cavity in BN rats. Acoustic rhinometry is a method for 
the measurement of the volume of the nasal cavity based 
on the acoustic reflection technique for determining the 
cross-sectional area as a function of distance in the upper 
airways. A) Diagram of the apparatus in acoustic rhinometry 
for smal animals. B) Typical area-distance curve obtained 
by acoustic rhinometry. The laticed area indicates the vol-
ume of the nasal cavity.
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reports on nasal obstruction models using rats. It was
expected that BN rats would show an obvious nasal
obstruction like guinea pigs because of its Th2-
dominant immunological properties．
Allergic inflammation should be an important
pathogenesis of not only asthma , but also allergic
rhinitis.16 The allergic inflammation can be induced
by cytokines such as IL-4, IL-13 and IL-5 produced
from Th2 lymphocytes , cationic proteins and
prostanoids released from eosinophils, and chemical
mediators, cytokines and chemokines released from
mast cells. Phosphodiesterase (PDE) 4 inhibitors in-
hibit such allergic inflammation both in in vitro and
in vivo studies . 17-21 Indeed , the effects of several
PDE4 inhibitors have been reported not only in ani-
mal models, but also in clinical studies.22
KF19514 is a PDE1 and 4 dual inhibitor. Its IC50
values in PDE1 and 4 derived from canine smooth
muscle are 400 and 270 nmolL , respectively .
KF19514 inhibited antigen-induced bronchoconstric-
tion and airway eosinophilia in guinea pigs. It also in-
hibited antigen-induced airway hyperresponsiveness
at 100 μgkg, p.o.23,24
The present study was done i) to establish a simple
model of allergic nasal obstruction in sensitized BN
rats , and ii ) to evaluate PDE 4 inhibitors in this
model．
METHODS
ANIMALS
Specific pathogen-free male BN rats (aged 5 weeks)
were purchased from Charles River Japan (Yoko-
hama, Japan). All studies were performed in accor-
dance with protocols approved by the Animal Ethical
Committee of the Pharmaceutical Research Institute
of Kyowa Hakko Kogyo Co., Ltd．
REAGENTS
Chicken egg albumin (OVA ; Grade III ; Sigma-
Aldrich, St. Louis, MO, USA), aluminium hydroxide
(Wako Pure Chemicals, Tokyo, Japan) and urethane
(Nippon Kasei Chemical, Tokyo, Japan) were used.
Chlorpheniramine and prednisolone were purchased
from Sigma-Aldrich. Rolipram, CDP-840 and KF19514
were synthesized in our laboratories．
SENSITIZATION AND INTRANASAL CHAL-
LENGEWITH OVA
BN rats were intraperitoneally sensitized with a 1-mL
mixture of 1 mgmL OVA and 100 mgmL alumin-
ium hydroxide in saline on day 1 and 3. Three weeks
after the last sensitization, rats were challenged with
the antigen under anesthesia with urethane
( 1.2 gkg,i.p.). Ten μL of 5% OVA-saline solution was
instilled into the bilateral nostrils with a micropipette
for antigen-challenge. It was dropped as a bead of
fluid on the nostrils, which allowed the rats to aspi-
rate it. Sham-challenged rats received 10 μL of saline
in the same manner. All drugs, except for predniso-
lone, suspended in 0.5% methylcellulose (Wako Pure
Chemicals) were given orally in a volume of 10 mL
kg weight 1 hour before the challenge. Prednisolone
was given 1.5 hours before the challenge．
EVALUATION OF ANTIGEN-INDUCED NASAL
OBSTRUCTION
Decrease in the volume of the nasal cavity was taken
as nasal obstruction. The volume of the nasal cavity
was measured by acoustic rhinometry . An acoustic
rhinometer (GJ Elektronik, Skanderborg, Denmark)
was modified by arranging its nosepiece for rats (Fig.
1A). In acoustic rhinometry, a sound pulse created by
a spark generator in a wave tube connected with the
nasal cavity reflects from the nasal cavity , and the
acoustic reflections are measured as a function of the
distance from the nostril (Fig. 1B). From this reflec-
tion curve, the volume of the nasal cavity from the en-
trance of the nostril to 1.75 cm depth (the average
value from anatomical specimens ) was calculated
with a computer for each measurement. For each ani-
mal, the mean value of 3 measurements for each nos-
tril was regarded as the volume. The nasal obstruc-
tion of each animal was evaluated by the sum of the
decreases in volume of the left and right nasal cavi-
ties. The nasal obstruction was expressed as the per-
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Fig. 2　Time course of the % decrease in the volume of the 
nasal cavity after saline (open circle) or antigen chalenge 
(closed circle) in actively sensitized BN rats. Saline or anti-
gen solution was instiled 10 μL into the bilateral nostrils of 
the sensitized rats. The volume of the nasal cavity was 
measured with an acoustic rhinometer. Data represent the 
means ± S.E.M. of 8 rats.  ＊, ＊＊, ＊＊＊: p < 0.05, 0.01 and 
0.001 vs. pre value by paired t-test, respectively.  #, ###: p 
< 0.05 and 0.001 vs. the saline group by Student’ st-test or 
the Aspin-Welch test, respectively.
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Fig. 3　Efects of chlorpheniramine (A) and prednisolone 
(B) on the antigen-induced nasal obstruction in actively sen-
sitized BN rats. Ten μL of saline or antigen solution was in-
stiled into the bilateral nostrils of the sensitized rats. 
Chlorpheniramine or prednisolone was given oraly 1 hour 
or 1.5 hours before the chalenge, respectively. The volume 
of the nasal cavity was measured with an acoustic 
rhinometer. Data represent the means ± S.E.M. of 4―5 rats. 
 ###: p < 0.001 vs. the saline group by Student’ st-test or 
the Aspin-Welch test. ＊＊, ＊＊＊: p < 0.05, 0.01 and 0.001 vs. 
the chalenge group by the Dunnet or the Steel test, 
respectively.
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centage change from the basal volume of the nasal
cavity. The basal volume of the nasal cavity was meas-
ured under anesthesia before the antigen challenge．
STATISTICAL ANALYSIS
All data are expressed as means ± S.E.M. Student’s t-
test or the Aspin-Welch test was used for the analysis
of the difference between saline-instilled and antigen-
challenged groups . Dunnett’s or Steel’s multiple
range test was used for the analysis of the drug effec-
tiveness. A probability value less than 5% was consid-
ered as statistically significant . ID50 values ( dose
yielding 50% inhibition ) were estimated by Probit
method (logistic model)．
RESULTS
CHANGES IN THE VOLUME OF THE NASAL
CAVITY AFTER THE ANTIGEN CHALLENGE
The volume of the nasal cavity was measured just be-
fore and 0.5, 3, 6 and 9 hours after the antigen chal-
lenge. The basal volume in the saline-instilled group
(30.7 ± 0.2 μL ) was not different from that in the
antigen-challenged group (30.4 ± 0.2 μL )．
The volume of the nasal cavity in sensitized and
challenged rats were significantly decreased with a
biphasic change peaking at 30 minutes (early phase
response ; EPR) and 6 hours (late phase response ;
LPR) after the antigen challenge (Fig. 2) , since the
percentage decreases of the volume of the nasal cav-
ity 30 minutes (14.3 ± 1.3% decrease from the base-
line), 6 hours (12.2 ± 0.8% decrease) and 9 hours
( 7.6 ± 1.6% decrease) after the antigen challenge
were significantly greater than in saline-instilled rats.
The volume of the nasal cavity 3 hours after the anti-
gen challenge did not decrease．
EFFECTS OF A HISTAMINE H1 ANTAGONIST
AND A GLUCOCORTICOID
Chlorpheniramine had little effect on the nasal ob-
struction in both EPR and LPR at 10 mgkg, the
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Fig. 4　Efects of rolipram (A) , CDP-840 (B) and KF19514 
(C) on the antigen-induced nasal obstruction in actively sen-
sitized BN rats. Ten μL of saline or antigen solution was in-
stiled into the bilateral nostrils of the sensitized rats. 
Rolipram, CDP-840 or KF19514 was oraly given 1 hour be-
fore the chalenge. The volume of the nasal cavity was 
measured with an acoustic rhinometer. Data represent the 
means ± S.E.M. of 4―6 rats.  ###: p < 0.001 vs. the saline 
group by Student’ st-test or the Aspin-Welch test.  ＊, ＊＊, 
＊＊＊ : p < 0.01 and 0.001 vs. the chalenge group by the 
Dunnet or the Steel test, respectively.
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doses sufficient for its histamine H1 antagonistic ac-
tivity (Fig. 3A) . Prednisolone significantly inhibited
both EPR and LPR. The inhibitory effect of predniso-
lone on LPR (50.4% at 30 mgkg ) was more potent
than that on EPR (39.5% at 30 mgkg ) (Fig. 3B). The
ID50 value of prednisolone in LPR was 30.4 mgkg (
Table 1).
EFFECTS OF PDE4 INHIBITORS
Rolipram (Fig. 4A) and CDP-840 (Fig. 4B) at 100 mg
kg significantly inhibited both EPR and LPR .
KF19514 markedly inhibited both EPR and LPR more
than 70% at 1 and 10 mgkg (Fig. 4C). The ID50 val-
ues of rolipram, CDP-840 and KF19514 in EPR were
62.7, 64.7 and 0.34 mgkg, respectively. Those of rol-
ipram, CDP-840 and KF19514 in LPR were 41.2, 59.4
and 0.59 mgkg, respectively (Table 1).
DISCUSSION
The present study provided a simple model of allergic
biphasic nasal obstruction in BN rats. The specific an-
tigen induced EPR and LPR, mimicking the early and
late phase nasal obstructions in patients with allergic
rhinitis.25 It was suggested that this model depends
on inflammation, characterized by the evaluation with
a histamine H1 antagonist and a steroid. This model
made it possible to evaluate anti-inflammatory drugs
for allergic rhinitis easily by using rats. Several PDE4
inhibitors were evaluated in this model．
We previously reported an experimental allergic
rhinitis model using guinea pigs which demonstrated
a sneezing, nasal rubbing, nasal secretion and nasal
obstruction.12,13 Nasal obstruction was evaluated by
measuring the decrease in the volume of the nasal
cavity using acoustic rhinometry. Guinea pigs are not
sensitive to glucocorticoids because of their high in-
ternal glucocorticoids.26 On the other hand, BN rats
are suitable to investigate the mechanism of the aller-
gic inflammation because of their high Th2-dominant
immunological profiles.27,28 BN rats have been used
to evaluate various types of drugs for asthma includ-
ing steroids, because the rats are sensitive to gluco-
corticoids and produce a biphasic bronchoconstric-
tion by the specific antigen provocation.29 In addition,
rat models are becoming more useful as many immu-
nological reagents including recombinant cytokines
and monoclonal antibodies have become available.
To adapt the acoustic rhinometry system to rats,
the nosepiece used for guinea pigs was modified to fit
rat nostrils. The nosepiece for rats has an elastic head
(diameter of 2.0 mm ) to perfectly fit the nostrils. In
addition, the body posture is critical for measuring
the volume of the nasal cavity in rats as well as in hu-
mans.30 It is recommended to measure the volume of
the nasal cavity of rats lying on their backs for good
reproducibility, though it is still unclear that the vol-
ume in this position represents the physiological vol-
ume. The reproducibility of the measurement of the
volume of the nasal cavity was confirmed by blind
tests (data not shown)．
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Table 1 The values of inhibition % and ID50 in early and late phase nasal obstructions 
 ID50 (mg/kg)Inhibition (% of control)
(mg/kg, p.o.)
LPREPR6 h (LPR)0.5 h (EPR)
― >100
 <0% <0% 1
chlorpheniramine  <0% <0% 10
 <0% 38.3%＊＊ 100
30.4 >30
 2.2% 10.3% 3
prednisolone  9.3% 9.6% 10
 50.4%＊＊＊ 39.5%＊＊ 30
41.2 62.7
 13.3% 20.8% 10
rolipram  41.2% 25.8% 30
 75.1%＊＊ 64.2%＊＊＊ 100
59.4 64.7
 14.4% 2.5% 10
CDP-840  24.5% 28.6% 30
 67.9%＊＊＊ 63.7%＊＊＊ 100
0.6 0.3
 17.8% 32.4%＊＊ 0.1
KF19514  71.3% 72.1%＊＊＊ 1
 79.7%＊ 73.3%＊＊＊ 10
Each data represents the mean ± S.E.M. of 4―6 rats. ＊, ＊＊, ＊＊＊: p < 0.01, 0.05 and 0.001 vs. the chalenge group by the Dunnet or 
the Steel test, respectively. 
In animal models, the nasal secretion and nasal ob-
struction appear at the same time. In fact, we have
seen these symptoms in our experiments with guinea
pigs. In guinea-pig models, we measured the nasal
cavity volume after the removal of nasal secretion by
aspiration. On the other hand, in sensitized BN rats,
nasal secretion was not elicited as much, though the
nasal obstruction was clearly induced by the antigen
challenge. In contrast with guinea pigs, sneezing and
nasal rubbing were not observed at all in sensitized
conscious BN rats by antigen instillation which is suf-
ficient to induce the nasal obstruction. Though nasal
secretion was observed only rarely in BN rats, such
rats were easily selected by acoustic wave pattern. In
such a case, we removed their nasal secretion by as-
piration before measuring nasal volume．
Intranasal antigen instillation induced a biphasic
nasal obstruction in sensitized BN rats peaking at 30
minutes and 6 hours after the challenge . This ob-
struction corresponds to the biphasic one in patients,
developing not only at 10―60 minutes but also at 5―10
hours after the intranasal antigen challenge 25 and
producing approximately 15―20% of decrease in the
volume of the nasal cavity. Chlorpheniramine, a clas-
sical H1 antagonist, did not inhibit either response at
doses sufficient for showing its anti-histaminic ef-
fects. The result that prednisolone inhibited both re-
sponses suggests the contribution of inflammatory
mechanisms to the development of the nasal obstruc-
tion. These results are in agreement with the clinical
observations that the nasal obstruction in patients
with allergic rhinitis cannot be well controlled by anti-
histamines, but by steroids.31-33 In addition, inflamma-
tory mechanisms play a role in the development of
the nasal obstruction mainly on LPR, since predniso-
lone shows a more potent inhibitory effect on LPR by
50.4% inhibition than on EPR by 39.5% inhibition at 30
mgkg.
There have been no reports on the efficacy of
PDE4 inhibitors in experimental allergic rhinitis mod-
els. On the other hand, the beneficial effects of PDE4
inhibitors in allergic asthma have been shown in pre-
vious preclinical and clinical studies.22 PDE4 inhibi-
tors might also be effective in allergic rhinitis , be-
cause allergic rhinitis and asthma share several epi-
demiological and pathophysiological factors. The pre-
sent study clearly demonstrates that three PDE4 in-
hibitors are effective in blocking both early and late
phase nasal obstructions. In addition, the inhibitory
effects of PDE4 inhibitors on both EPR and LPR were
more potent than those of steroids. It might also be
acceptable that KF19514 inhibited the reactions via
PDE1 inhibition. However, it was reported that vinpo-
cetine, a PDE1 inhibitor, did not inhibit allergic reac-
tions.23 It is therefore expected that PDE1 inhibitory
activity of KF19514 contributes little to the inhibitory
effect on nasal obstruction.
On the other hand, a series of evidence, high con-
centrations of prostanoids in the nasal lavage fluid af-
ter the antigen challenge in patients with allergic
rhinitis34,35 and induction of nasal obstruction by cys
teinyl leukotrienes , 36 thromboxane A2 37 and
prostaglandin D2,38 have demonstrated their impor-
tant role in the development of the nasal obstruction.
In addition, we have shown that both cysteinyl leukot-
riene receptor antagonist and thromboxane A2 recep-
tor antagonist inhibited antigen-induced nasal ob-
structions on EPR in sensitized guinea pigs. 39 Fur-
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thermore, the late phase nasal response has been rec-
ognized as an important clinical phenomenon in pa-
tients with chronic allergic rhinitis associated with
lasting edema of the nasal membrane mucosa, and
nasal mucosal infiltrates consisting mainly of eosino-
phils.25 It was reported that a PDE4 inhibitor inhib-
ited allergic eosinophilia and release of prostanoids
from mast cells and eosinophils . 17-24 It is therefore
considered that the potent inhibitory effects of PDE4
inhibitors against the biphasic nasal obstruction are
led by the decrease of prostanoid release induced by
anaphylaxis on EPR, and by the prevention of eosino-
phil infiltration into the nasal mucosa and of
prostanoid release from those cells on LPR. Indeed, it
was recently reported that a PDE4 inhibitor effec-
tively controlled symptoms of patients with allergic
rhinitis.40
In conclusion, we have demonstrated a simple rat
model of allergic nasal obstruction, which develops
early and late phase responses. The obstructions do
not depend on histamine, but on inflammation. PDE4
inhibitors clearly prevented the allergic nasal obstruc-
tion in both phases in our rat model. PDE4 inhibitors
may be useful for treatment of allergic rhinitis.
REFERENCES
1. Kozma CM, Sadik MK, Watrous ML. Economic outcomes
for the treatment of allergic rhinitis. Pharmacoeconomics
1996;10:4-13.
2. Sibbald B, Rink E. Epidemiology of seasonal and peren-
nial rhinitis : clinical presentation and medical history.
Thorax 1991;46:895-901.
3. Iliopoulos O, Proud D, Adkinson NF Jr et al. Relationship
between the early, late, and rechallenge reaction to nasal
challenge with antigen : observations on the role of in-
flammatory mediators and cells. J. Allergy Clin. Immunol.
1990;86:851-861.
4. Naclerio RM. Allergic rhinitis. N. Engl. J. Med. 1991;325:
860-869.
5. Ukai K, Amesara R, Sakakura Y. Nasal hypersensitivity
and reactivity to histamine in guinea pigs. Jpn. J. Allergol.
1987;36:386-393.
6. Hustaon PA, Church MK, Clay TP, Miller P, Holgate ST.
Early and late phase bronchoconstriction after allergen
challenge of nonanesthetized guinea pigs : 1. The asso-
ciation of disordered airway physiology to leukocyte infil-
tration. Am. Rev. Respir. Dis. 1988;137:548-557.
7. Sherwood JE, Hutt DA, Kreutner W, Morton JB, Chap-
man RW. A magnetic resonance imaging evaluation of
histamine-mediated allergic response in the guinea pig
nasopharynx. J. Allergy Clin. Immunol. 1993;92:435-441.
8. Hilberg O. Objective measurement of nasal airway dimen-
sions using acoustic rhinometry : methodological and
clinical aspects. Allergy 2002;57:5-39.
9. Hilberg O, Jackson AC, Swift DL, Pedersen OF. Acoustic
rhinometry : evaluation of nasal cavity geometry by
acoustic reflection. J. Appl. Physiol. 1989;66:295-303.
10. Pedersen OF, Yamagiwa M, Miyahara Y, Sakakura Y. Na-
sal cavity dimensions in guinea pigs measured by acous-
tic reflections. Am. J. Rhinology 1994;8:299-304.
11. Kaise T, Ukai K, Pedersen OF, Sakakura Y. Accuracy of
measurement of acoustic rhinometry applied to small ex-
perimental animals. Am. J. Rhinol. 1999;13:125-129.
12. Kaise T, Ohmori K, Sakakura Y, Ukai K. The effect of
KW-4679, an antiallergic drug, on experimental allergic
rhinitis in guinea pigs : effects on nasal blockage. Jpn. J.
Pharmacol. 1995;69:435-438.
13. Kaise T, Akamatsu Y, Ohmori K. Effect of oxatomide on
experimental allergic rhinitis in guinea pigs. Jpn. J. Phar-
macol. 1998;76:223-226.
14. Kaise T, Akamatsu Y, Ikemura T, Ohmori K, Ishii A,
Karasawa A. Involvement of neuropeptides in the allergic
nasal obstruction in guinea pigs. Jpn. J. Pharmacol. 2001;
86:196-202.
15. Schneider T, van Velzen D, Moqbel R, Issekutz AC. Ki-
netics and quantitation of eosinophil and neutrophil re-
cruitment to allergic lung inflammation in a brown Nor-
way rat model. Am. J. Respir. Cell Mol. Biol. 1997;17:702-
712.
16. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiap-
parino A, Testi R. Once daily fluticasone propionate (200
micrograms) reduces nasal symptoms and inflammation
but also attenuates the increase in bronchial responsive-
ness during the pollen season in allergic rhinitis. J. Allergy
Clin. Immunol. 1996;98:274-282.
17. Verghese MW, McConnell RT, Strickland AB et al. Differ-
ential regulation of human monocyte-derived TNF-α and
IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE)
inhibitors. J. Pharmacol. Exp. Ther. 1995;272:1313-1320.
18. Souness JE, Houghton C, Sardar N, Withnall MT. Sup-
pression of anti-CD3-induced interleukin-4 and interle-
ukin-5 release from splenocytes of Mesocestoides corti-
infected BALBc mice by phosphodiesterase 4 inhibitors.
Biochem. Pharmacol. 1999;58:991-999.
19. Denis D, Riendeau D. Phosphodiesterase 4-dependent
regulation of cyclic AMP levels and leukotriene B4 bio-
synthesis in human polymorphonuclear leukocytes. Eur.
J. Pharmacol. 1999;367:343-350.
20. Jones TR, McAuliffe M, McFarlane CS, Piechuta H, Mac-
donald D, Rodger IW. Effects of a selective phosphodi-
esterase 4 inhibitor (CDP-840) in a leukotriene-dependent
non-human primate model of allergic asthma. Can . J .
Physiol. Pharmacol. 1998;76:210-217.
21. Torphy TJ. Phosphodiesterase isozymes : molecular tar-
gets for novel antiasthmatic agents. Am. J. Respir. Crit.
Care Med. 1998;157:351-370.
22. Giembycz MA. Phosphodiesterase 4 inhibitors and the
treatment of asthma. Drugs 2000;59:193-212.
23. Manabe H, Akuta K, Sejimo H et al. Anti-inflammatory a-
nd bronchodilator properties of KF19514, a phosphodie-
sterase 4 and 1 inhibitor. Eur. J. Pharmacol. 1997;332:97-
107.
24. Manabe H, Akuta K, Kawasaki H, Ohmori K. The inhaled
administration of KF19514, a phosphodiesterase 4 and 1
inhibitor, prevents antigen-induced lung inflammation in
guinea pigs. Pulm. Pharmacol. Ther. 2000;13:5-11.
25. Terada N, Konno A, Togawa K. Biochemical properties of
eosinophils and their preferential accumulation mecha-
nism in nasal allergy. J. Allergy Clin. Immunol. 1994;94:
629-642.
26. Pytsky VI. Cortisol-resistant lymphocytes in experimental
allergic processes and some diseases in men. Allergol. Im-
munopathol. 1983;11:435-443.
27. Murphey SM, Brown S, Miklos N, Fireman P. Reagin syn-
thesis in inbred strains of rats. Immunology 1974;27:245-
253.
28. Pauwels R, Bazin H, Platteau B, van der Straeten M. The
432 Allergology International Vol 54, No3, 2005 www.js-allergol.gr.jp
Kawasaki H et al.
influence of antigen dose on IgE production in different
rat strains. Immunology 1979;36:151-157.
29. Renzi PM, Olivenstein R, Martin JG. Inflammatory cell
populations in the airways and parenchyma after antigen
challenge in the rat. Am. Rev. Respir. Dis. 1993;147:967-
974.
30. Hilberg O, Pedersen OF. Acoustic rhinometry : recom-
mendations for technical specifications and standard op-
erating procedures. Rhinol. Suppl. 2000;16:3-17.
31. Simons FER. H1-receptor antagonists : Clinical pharma-
cology and therapeutics. J. Allergy Clin. Immunol. 1989;
84:845-861.
32. Pelikan Z. The effects of disodium cromoglycate and be-
clomethasone dipropionate on the late mucosa response
to allergen challenge. Ann. Allergy 1982;49:200-212.
33. Davies RJ, Lozewicz S, Manolitsas N, Calderon M, De-
valia JL. Inflammatory cell recruitment following allergen
exposure. In: Godard Ph, Bousquet J, Michel FB (eds) .
Advances in Allergology and Clinical Immunology. Carn-
forth: The Parthenon Publ. Group, 1992;233-243.
34. Naclerio RM, Proud D, Togias AG et al. Inflammatory me-
diators in late antigen-induced rhinitis. N. Engl. J. Med.
1985;313:65-70.
35. White MV, Kaliner MA. Mediators of allergic rhinitis. J .
Allergy Clin. Immunol. 1992;90:699-704.
36. Cho JS, Cha CI, Lee DY, Ukai K, Sakakura Y. The effect
of leukotriene D4 on the patency of nasal passage in the
guinea pig. Am. J. Rhinol. 1998;12:421-425.
37. Yamasaki M, Mizutani N, Sasaki K et al. Involvement of
thromboxane A2 and peptide leukotrienes in early and
late phase nasal blockage in a guinea pig model of allergic
rhinitis. Inflamm. Res. 2001;50:466-473.
38. Arimura A, Yasui K, Kishino J et al. Prevention of allergic
inflammation by a novel prostaglandin receptor antago-
nist, S-5751. J. Pharmacol. Exp. Ther. 2001;298:411-419.
39. Kawasaki H, Kaise T, Akamatsu Y, Nishikawa H, Ohmori
K. [The inhibitory effects of oxatomide on allergic rhinitis
model in sensitized guinea pigs.] Allergology and Immu-
nology 2000;7:90-97(in Japanese).
40. Schmidt BM, Kusma M, Feuring M et al. The phosphodi-
esterase 4 inhibitor roflumilast is effective in the treat-
ment of allergic rhinitis. J. Allergy Clin. Immunol. 2001;
108:530-536.
Allergology International Vol 54, No3, 2005 www.js-allergol.gr.jp 433
PDE4 Inhibitors Prevent Rhinitis in Rats
